A synthetic glucocorticoid corticosteroid..

A small molecule, selective FOXO1 inhibitor that inhibits FOXO-dependent glucose production devoid of lipogenic activity in hepatocytes.

A rocaglate (flavagline) derivative that acts a highly specific inhibitor of the oncogenic translation program supporting MM, including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1.

A potent, subtype-selective, orally available eIF4A3 inhibitor with IC50 of 0.14 uM.

A potent, selective, CNS penetrant, orally bioavailable RORγt with pIC50 of 8.3 in FRET assays.

A novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer.

A novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer.

A novel small molecule KLF5 inhibitor derived from ML264, demonstrates >10-fold enhanced efficacy in multiple cancer cell lines with IC50 of 1.5-10 uM.

A novel potent, selective Nrf2 activator with pEC50 of 7.7 (inducing of NQO1 specific enzyme activity).

A novel potent, orally active HIF prolyl hydroxylase (PHD) inhibitor with IC50 of 0.22 uM for PHD2.

A novel potent, non-agonist PPARγ ligand that blocks CDK5-mediated PPARγ phosphorylation, without the classical agonism.

25-Hydroxyvitamin D2 is used in serum to measure the concentration of vitamin D produced by the skin. It is known that 25-Hydroxyvitamin D2 can be detected in human serum using high-performance liquid chromatography and ultraviolet detection. Vitamin D2,

22-Oxacalcitriol is a Vitamin D3 analog which is Non-calcemic as well as a VDR ligand. 22-Oxacalcitriol has been shown to decrease parathyroid hormone (PTH) mRNA expression in vitro. Additionally has been noted to exhibit similar effects to calcitriol in

>98%,Standard References

>98%,Standard References